



## Supplementary Information for

### **Rationally engineered *Staphylococcus aureus* Cas9 nucleases with high genome-wide specificity**

Yuanyan Tan\*, Athena H. Y. Chu\*, Siyu Bao, Duc Anh Hoang, Firaol Tamiru Kebede, Wenjun Xiong, Mingfang Ji, Jiahai Shi, Zongli Zheng

Correspondence: Jiahai Shi and Zongli Zheng  
Email: Jiahai.Shi@cityu.edu.hk; ZhengZongli@gmail.com

#### **This PDF file includes:**

- Supplementary Material and Methods
- Figures S1 to S8
- Tables S1 to S5
- References

## Supplementary Material and Methods

**Protein structure analysis** Pymol (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.) was used to view protein structure of SaCas9 (PDB ID 5AXW and 5CZZ) and calculate polar contact between proteins and DNA.

**Plasmids and oligonucleotides.** The plasmid BPK2139 (Addgene #65776) was used to express WT-SaCas9 and variant mutagenesis. All mutant SaCas9 (including S-HF) expression plasmids (Table S1) were constructed by site-directed mutagenesis using BPK2139 as the backbone (Guangzhou IGE biotechnology Ltd.). High-fidelity SpCas9 variant expressing plasmids were purchased from Addgene (eSpCas9(1.1), #71814, SpCas9-HF1 #72247 and HyPa-Cas9 #101178). Sequences of mutated plasmids were confirmed by Sanger sequencing. The sgRNA expression plasmids for SaCas9 were constructed by ligating oligonucleotide duplexes (synthesized by BGI Tech Solution Co. Ltd.) of the sgRNA (Table S2, S3) into BsmBI digested BPK2660 plasmid (Addgene #70709). The sgRNA expression plasmids for SpCas9 were constructed by ligating sgRNA into BsmBI digested BPK1520 plasmid (Addgene #65777). All plasmids were purified with the PureLink™ HiPure Plasmid Midiprep Kit (Invitrogen) and quantified by NanoDrop 2000.

**Cell culture and transfection.** The 293T cells were purchased from ATCC (CRL-3216), and the 293T-EGFP cell was a gift from Dr. Minh Le of City University of Hong Kong. Cells were cultured in advanced DMEM medium (Life Technologies) with 10% fetal bovine serum (Biosera) and 1% antibiotic (Life Technologies) in 5% CO<sub>2</sub> cell culture incubator. Transfection were performed using PEI (*Polyethylenimine*) for 293T following the manufacturer's instruction.  $7.5 \times 10^4$  cells were transfected with a total of 400 ng SaCas9 plasmid DNA and 400 ng sgRNA plasmid in 24-well plate. WT-SaCas9 was co-transfected with a U6-null BPK2660 plasmid as the no-sgRNA negative control.

**DNA extraction.** Genomic DNA were extracted using the MiniBEST Universal Genomic DNA Extraction Kit (TaKaRa), and quantified using the Qubit 3.0 fluorometer and Qubit™ dsDNA HS Assay Kit (Invitrogen).

**Targeted deep sequencing.** Genomic regions (listed in Table S2) encompassing on-target sites of the 27 sgRNA examined (Table S2, S3) and a selection of off-target sites targeted by VEGFA\_8, FANCF\_13, EMX1\_6 and RUNX1\_13 were subjected to amplicon sequencing to evaluate editing efficiency of the SaCas9. Specifically, genomic DNA (20 ng for on-target site and 10 ng for off-target site) was used for PCR using target specific forward/reversed primers (Table S4) and Platinum Taq DNA polymerase (Thermo Fisher Scientific) by the following condition: 95°C for 5 min, 14 cycles of [95°C for 30 sec, 72°C touchdown at -1°C per cycle for 1 min], 20 cycles of [95°C for 30 sec, 58°C for 1 min], 72°C for 3 min and hold at 4°C. The product was used for a second PCR step to introduce Illumina sequencing sequences by the following condition: 95°C for 5 min, 20 cycles of [95°C for 30 sec, 65°C for 1 min], 72°C for 3 min and hold at 4°C. The sequencing libraries were quantified by qPCR (KAPA Library Quantification Kits for Illumina) and sequenced on Illumina NextSeq 500 System using 300-cycle kit

for 2x150 sequencing. The FASTQ reads were aligned to the human reference genome GrCh37 using BWA MEM<sup>1</sup> with default parameters. High-quality mapped read pair (properly mapped read-pair that contain at least 30 bp of matching alignment to the reference genome) were used for assessing the editing efficiency. Editing efficiency for each SaCas9 variant was measured as the number of reads containing InDels within the surveyed site, excluding the PCR primer annealing regions, divided by the total number of reads spanning the surveyed site, using an in-house Python script.

**EGFP disruption assay.** EGFP disruption assays were performed to assess on-target activity of wild-type and mutant SaCas9s with the sgRNA targeted to EGFP gene in the 293T-EGFP cell. Briefly,  $7.5 \times 10^4$  293T-EGFP cells were transfected with 500 ng WT or mutant SaCas9 expressing plasmid and 250 ng of EGFP targeted sgRNA (either with or without mismatches to the target site) expression plasmid. The 293T-EGFP cell co-transfected with SaCas9 expression plasmid and the U6-null plasmid was used as baseline negative control for SaCas9 editing. The fluorescence of the transfected cells was measured by flow cytometry. On-target efficiency is measured as the loss of fluorescence upon co-transfection of sgRNA and SaCas9 expression plasmids and normalized to the mentioned negative control.


**GUIDE-seq.** Genomic DNA were extracted 72 h post-transfection and 400 ng was used for NGS library construction following the GUIDE-seq<sup>2</sup> methods with minor modification. Briefly, DNA was enzymatically fragmented by KAPA Frag Kit (KAPA Biosystems), followed by adaptor ligation and two rounds of hemi-nested PCR enrichment for dsODN integration fragments. To unify Illumina sequencing workflows for obtaining dual indexed data using Single-Indexed sequencing workflow across various Illumina platforms, we redesigned the original half-functional adaptors<sup>3</sup> and placed sample index (Index 2) at the head of Read 1, following unique molecular index (Table S5). Final sequencing libraries were quantified by qPCR (KAPA Library Quantification Kits for Illumina) and sequenced on Illumina NextSeq 500 System. Data demultiplexing of Index 1 was performed by bcl2fq v2.19, followed by custom scripts for Index 2 demultiplexing, adaptor trimming using the BBduk tool<sup>4</sup>, and formatting for analysis using the GUIDE-seq software<sup>5</sup>. Briefly, demultiplexed and unique molecular index (UMI)-tagged FASTQ data was consolidated to generate UMI-consensus sequence, and aligned to human reference genome GrCh37 using BWA MEM<sup>1</sup>. High-quality alignments (MAPQ  $\geq$  50) were used for identifying genomic regions with the dsODNs integration as SaCas9 edited sites. Off-target sites with up to 7 mismatches edited by SaCas9, and 6 mismatches edited by SpCas9 within the protospacer region were identified.

**AAV transduction** The plasmid pAAV-CMV-SaCas9-2A-mCherry-U6-Bsal-sgRNA was cloned by PCR amplifying the 2A-mCherry fragment (Forward primer: 5'-CGCGGATCCGAGGGCAGAGGCAG-3'; reverse primer: 5'-CCGGAATTCTTACTTGTACAGCTCGTCCATGC-3') and ligating it via BamHI/EcoRI sites into the backbone plasmid pAAV-CMV-SaCas9-U6-Bsal-sgRNA (Addgene #61591). The WT-SaCas9 human optimized codon (pCAG-WT-SaCas9) was obtained from Addgene (Addgene #65776). The WT-SaCas9 or SaCas9-HF was cloned


into the pAAV-CMV-SaCas9-2A-mCherry-U6-Bsal-sgRNA to replace the original SaCas9 via AgeI/XhoI sites. The *VEGFA* gRNA was inserted into the pAAV backbone via BsaI sites. The control vector pAAV-CMV-mCherry-U6 *Rho* gRNA was used. For packaging AAV8 virus, pAAV rep/Cap2/8 and adenovirus helper plasmids were obtained from the University of Pennsylvania Vector Core (Philadelphia, USA). Recombinant AAV8 vectors were produced as previously described<sup>6</sup>. Briefly, pAAV vector plasmid, rep/cap 2/8 packaging plasmid, and adenoviral helper plasmid were mixed with polyethylenimine (PEI) with a ratio of DNA:PEI=1:3 in DMEM. The mixture was incubated 15 min at room temperature and added to HEK293T cells (HCL4517; Thermo Scientific) cultured in DMEM with 2% NuSerum growth medium supplement (Corning). The transfected medium was replaced by DMEM after 24 hours, and the supernatant was collected at 72 hours after transfection. The AAV8 virus supernatant was precipitated (mixed with 8.5% wt/vol PEG-8000 and 0.4 M NaCl for 2h at 4 °C), centrifuged at 7,000 × *g* for 10 min, and resuspended in virus buffer (150 mM NaCl and 20 mM Tris, pH 8.0). The virus supernatant was ultra-centrifuged under iodixanol gradient at 147,000 × *g* at 4°C for 90 min. The collected fraction of AAV8 vectors (40% iodixanol fraction) were washed three times with PBS using Amicon 100K columns (EMD Millipore). The virus titers were quantified by protein SDS-PAGE gel and SYPRO® Ruby protein gel stain (Thermo Fisher Scientific).

ARPE-19 (ATCC® CRL-2302™) cells were cultured in DMEM/F12 with 10%FBS and incubated at 37 °C , 5% CO<sub>2</sub>. ARPE-19 cells were transduced with AAV8 vectors as described by the Viral Vector Core Facility, University of Iowa Health Care. In brief, the AAV8 vectors were diluted in transduction medium (DMEM/F12, 2% FBS, 2μM Hoechst-33342) at room temperature and inoculated at 10<sup>5</sup> viral genomes per cell (vg/cell) of ARPE-19 cells incubated at 37°C, 5% CO<sub>2</sub>. The cells incubated with the transduction medium and without AAV vector transduction were used as the untransduction control. The transduction medium was replaced with full medium (DMEM/F12, 10% FBS) at 24 hours after transduction. The cells were harvested for genomic DNA extraction at 72 hours after transduction. Genomic DNAs were extracted by PureLink™ Genomic DNA Mini Kit (Thermo Fisher Scientific).


**Data analysis.** Sequencing data is deposited under the European Nucleotide Archive (PRJEB31487). We performed statistical analyses and graph plotting in R 3.5.2<sup>7</sup> using the dplyr<sup>8</sup>, tidyr<sup>9</sup>, ggplot2<sup>10</sup> and VennDiagram<sup>11</sup> packages.



**Fig. S1. Indel profile of SaCas9 targeting VEGFA\_8 in HEK293T cells.** IGV snapshots showing the insertions and deletions sequences of WT-SaCas9 editing in HEK293T **(a)** and the respective negative control of untreated cells **(b)**. Indel profiles **(c)** showing per base insertion and deletion percentages (y-axis) introduced by WT-SaCas9 and the four single mutants: R245A, N413A, N419A, and R654A. The x-axis specifies the protospacer position (21-1) followed by the NNGRRT PAM site.



**Fig. S2: Genome-wide editing results of WT and single-substitution SaCas9 variants at EMX1\_6, VEGFA\_8, and EMX1\_1 using GUIDE-seq.** Genome-wide cleavage sites detected by GUIDE-seq. Read counts listed in the right represent number of GUIDE-seq reads. On target site is indicated with “\*”. Mismatched bases in off-target sites with the on-target site are highlighted.




**Fig. S3. Epistasis effect of SaCas9 residues on targeting specificity.** Genome-wide cleavage of WT, double, triple, and quadruple mutant SaCas9s (mutation combination indicated in the top right panel) detected by GUIDE-seq at sites EMX1\_6, FANCF\_13 and VEGFA\_8. Read counts listed in the right represent the cleavage frequency at a given site; on target site is marked with \* for each sgRNA; mismatched positions are highlighted within the spacer or PAM.

Target	Sequence	GUIDE-seq reads			Targeted deep seq. InDel%		
		WT	R245A	SaCas9-HF	WT	R245A	SaCas9-HF
FANCF_10	21 19 17 15 13 11 9 7 5 3 1 G T A G G G C C T T C G C G C A C C T C A N N G R R T	241	313	274	13.5	10.1	8.6
RUNX1_13	21 19 17 15 13 11 9 7 5 3 1 G A A A G A G A G A T G T A G G G C T A G N N G R R T	493	1179	1570	27.2	34.8	34.8
	..... A G • G G • * ..... G T • A A •	3	-	-	OT1 <0.1*	NT	<0.1
RUNX1_14	23 21 19 17 15 13 11 9 7 5 3 1 G T A C T C A C C T C T C A T G A A G C A C T N N G R R T	881	99	654	40.7	40.5	36.6
EMX1_6	21 19 17 15 13 11 9 7 G C A A C C A C A A A C C C A C G A G G G N N G R R T	7032	4934	784	62.0	56.4	19.5
	A • • • • • T • • • • • C A • A G • * • • • • • T • • • • • C A • A G • • • • • • T • • • • • A • • • • A C A • A G • • • • • • T • • • • • A • • • • A A • A G G • • • • • • C • • • • • C C • • • • • A • • • • C A • G G • • • • • • C • T • • • • • C T • T T • G C • T G A •	2713	1647	19	OT1 5.0*	NT	0.3*
	• • • • • T • • • • • A • • • • • C A • A G •	789	321	-	OT2 2.2*	NT	<0.1
	• • • • • T • • • • • A • • • • • A • • • • • C A • G G •	43	-	-	OT3 <0.1	NT	<0.1
	• • • • • C • T • • • • • C T • T T • G C • T G A •	4	-	-	OT4 <0.1*	NT	<0.1
VEGFA_8	21 19 17 15 13 11 9 7 G G G T G A G T G A G T G T G T G C G T G N N G R R T	871	854	247	57.5	54.5	50.9
	..... T G • G G • * ..... G A • A G •	440	259	62	OT1 3.6*	NT	1.8*
	..... T G • G G •	400	66	-	OT2 1.5*	NT	<0.1
	..... A T • A G •	231	94	3	NT	NT	NT
	..... G T • A G •	188	64	4	NT	NT	NT
	..... G G • G G •	187	54	4	NT	NT	NT
	..... G T • A G •	184	45	-	OT4 3.6*	NT	<0.1
	..... G G • G G G •	169	45	-	NT	NT	NT
	..... G T • A G •	90	3	-	OT5 1.1*	NT	<0.1
	..... G T • A G •	86	11	-	NT	NT	NT
	..... G G • A G •	81	-	-	NT	NT	NT
	..... G T • A G •	77	11	-	OT3 1.3*	NT	<0.1
	..... G T • A G •	68	5	-	NT	NT	NT
	..... G T • A G •	58	8	-	NT	NT	NT
	..... T G • G G •	53	3	-	NT	NT	NT
	..... G T • A G •	49	7	-	NT	NT	NT
	..... G T • A G •	47	13	-	NT	NT	NT
	..... G T • A G •	46	8	-	NT	NT	NT
	..... G T • A G •	42	4	-	NT	NT	NT
	..... T T • A G •	39	6	-	NT	NT	NT
	..... A G T • G G •	33	-	-	NT	NT	NT
	..... G T • A G •	33	5	-	NT	NT	NT
	..... G T • G G •	32	3	-	NT	NT	NT
	..... G T • A G •	31	-	-	NT	NT	NT
	..... G T • A G •	27	7	-	NT	NT	NT
	..... G A • G G •	27	9	-	NT	NT	NT
	..... G T • G G •	25	9	-	NT	NT	NT
	..... G T • A G •	24	-	-	NT	NT	NT
	..... G T • A G •	23	-	-	NT	NT	NT
	..... G T • A G •	23	-	-	NT	NT	NT
	..... G T • A G •	20	-	-	NT	NT	NT
	..... A T • A A •	18	-	-	NT	NT	NT
	..... T T • G G G •	15	-	-	NT	NT	NT
	..... G T • A G •	15	-	-	NT	NT	NT
	..... G T • A G •	15	-	-	NT	NT	NT
	..... G T • A G •	13	-	-	NT	NT	NT
	..... G T • A G •	12	-	-	NT	NT	NT
	..... G A • A A •	12	-	-	NT	NT	NT
	..... G A • A T • G •	9	6	-	NT	NT	NT
	..... A G T • G A • G •	9	-	-	NT	NT	NT
	..... G T • A G •	9	-	-	NT	NT	NT
	..... A T • G G •	9	-	-	NT	NT	NT
	..... G T • A A •	7	-	-	OT10	NT	NT
	..... A C • A G •	5	-	-	OT7 #	NT	#
	..... G T • A G •	5	-	-	OT6 0.1*	NT	<0.1
	..... A G • A C • A •	4	-	-	OT8 0.1*	NT	<0.1
	..... T G • G G • G •	4	-	-	OT9 #	NT	#


**Fig. S4: Genome-wide editing specificity of wild-type SaCas9, R245A and quadruple mutants at five target sites with canonical NNGRRT PAM.** GUIDE-seq reads and InDel% detected in targeted deep sequencing for the on-target and off-target sites (in dark blue) are listed on the right. On target site is indicated with “\*” at the right of the target sequence. Mismatched bases in off-target sites with the on-target site are highlighted. “NT” indicates off-target sites not subjected to targeted deep sequencing; “#” indicates off-target sites prone to false positives in targeted deep sequencing and percentages were not calculated; and InDel% marked with “\*” indicates edited reads confirmed by IGV visualization.



**a**




**b**




**Fig. S5: Genome-wide on- and off-target activities of wild-type SaCas9 and SaCas9-HF when targeting additional 13 human endogenous sites with canonical NNGRRT PAMs.**

**a**, Genome-wide cleavage sites detected by GUIDE-seq. On target site is indicated with ‘\*’ at the right of the target sequence. Mismatched bases in off-target sites with the on-target site are highlighted. InDel% detected in targeted deep sequencing for the on-target (in dark blue) are listed. **b**, Percentage of edited reads detected by GUIDE-seq at on-target site (green) and off-target sites (ordered by number of mismatches) among total edited reads (top) and summary of numbers of off-targets at 13 NNGRRT-PAM sites by WT-SaCas9 and SaCas9-HF (bottom).




**Fig. S6: Genome-wide target profiles of WT-SaCas9, R245A and SaCas9-HF at non-canonical PAM sites.**

(a) GUIDE-seq of the non-NNGRRT sites EMX1-1, EMX1\_4, EMX1\_10, FANCF\_9 and FANCF\_16. Read counts listed in the right represent the cleavage frequency at a given site; on target site is marked with \* for each sgRNA; mismatched positions are highlighted within the spacer or PAM. (b) Summary bar chart of the genome-wide off-target detection of WT-SaCas9 (WT), SaCas9-R245A (R245A), SaCas9-HF (HF) at non-NNGRRT PAM sites: EMX1-1, EMX1\_4, EMX1\_10, FANCF\_9 and FANCF\_16. Each bar indicates the composition of dsODN integrated reads detected by GUIDE-seq for the SaCas9 variant; each stacked box shows the percentage of reads, as an approximation of cleavage frequency, at a target site with 0 (green) to 7 (red) mismatches. (c) A summary of the numbers of off-target sites.



**Fig. S7. On and off-target cleavage by KKH and KKH-HF at 6 canonical PAM human endogenous sites.**  
**a**, GUIDE-seq detected cleavage sites by KKH-SaCas9 and KKH-HF. Read counts listed in the right represent number of GUIDE-seq reads. On-target site is indicated with '\*'. Mismatched bases in off-target sites with the on-target site are highlighted. **b**, Venn diagram comparing the number of off-target sites between KKH-SaCas9 and KKH-HF in (a). **c**, Percentage of edited reads detected by GUIDE-seq at on-target site (green) and off-target sites (ordered by number of mismatches). **d**, Number of off-target sites in (c).



**Fig. S8: Performance comparison of high fidelity Sa- and Sp-Cas9 variants.**

Percentage of GUIDE-seq reads at on-target site (green) and off-target sites (ordered by number of mismatches) among total edited reads by each SaCas9 at each of the targeting site RUNX1\_13 and VEGFA\_8.

**Table S1. Expression plasmids of SaCas9 variants used in this study.**

<b>Plasmid name</b>	<b>Mutation site</b>
135-WT (BPK2139)	Wild-type SaCas9 without mutation.
135-2507-3011	R245A (2507 AG-GC), N413A (3011 AA-GC)
135-2507-3011-3029	R245A, N413A, N419A (3029 AA-GC)
135-2507-3011-3734	R245A, N413A, R654A (3734 AG-GC)
135-2507-3029	R245A, N419A
135-2507-3029-3734	R245A, N419A, R654A
135-2507-3734	R245A, R654A
135-3011-3029	N413A, N419A
135-3011-3029-3734	N413A, N419A, R654A
135-3011-3734	N413A, R654A
135-3029-3734	N419A, R654A
135-2507	R245A
135-3011	N413A
135-3029	N419A
135-3734	R654A
135-HF	R245A, N413A, N419A, R654A
135-S-HF	R499A, Q500A, R654A, G655A
135-KKH	G4118A, T4678A, G4818A
135-HF-KKH	R245A, N413A, N419A, R654A, G4118A, T4678A, G4818A

**Table S2. Human endogenous sites targeted in this study.**

Site	Spacer length (nt)	Genome location	Sequence of protospacer and PAM
EMX1_1	22	chr2+ 73160922-73160943	GTGTGGTTCCAGAACC GGAGGA <b>CAAAGT</b>
EMX1_4	21	chr2+ 73160833-73160859	GCTCAGCCTGAGTGTGAGGC <b>CCCAGT</b>
EMX1_6	21	chr2+ 73161089-73161109	GCAACCACAAACCCACGAGGG <b>CAGAGT</b>
EMX1_10	21	chr2- 73161274-73161300	GGCTCTCCGAGGAGAAGGCCA <b>AGTGGT</b>
FANCF_9	22	chr11+ 22647242-22647269	GCGCCCACTGCAAGGCCCGGCG <b>CACGGT</b>
FANCF_10	21	chr11- 22647350-22647376	GTAGGGCCTTCGCGCACCTCA <b>TGGAA</b>
FANCF_13	21	chr11+ 22647251-22647277	GCAAGGCCCGGCGCACGGTGG <b>CGGGGT</b>
FANCF_16	21	chr11+ 22647273-22647299	GGGTCCCAGGTGCTGACGTA <b>GGTAGT</b>
RUNX1_13	21	chr21- 36421296-36421322	GAAAGAGAGATGTAGGGCTAG <b>AGGGGT</b>
RUNX1_14	23	chr21+ 36421131-36421159	GTACTCACCTCTCATGAAGCACT <b>GTGGGT</b>
VEGFA_8	21	chr6+ 43737453-43737473	GGGTGAGTGAGTGTGTGCGCTG <b>TGGGGT</b>
AAVS1-2	20	chr19+ 55626992-55627017	GAGAGATGGCTCCAGGAAAT <b>TGGGGT</b>
AAVS1-3	20	chr19+ 55627180-55627205	GAGCCACATTAACCGGCCCT <b>GGGAAT</b>
AAVS1-4	20	chr19+ 55627076-55627101	GACTAGGAAGGAGGAGGCC <b>TAAAGAT</b>
AAVS1-5	20	chr19+ 55627033-55627058	GAATCTGCCCTAACAGGAGGT <b>GGGGGT</b>
CCR5-1	21	chr3 - 46413348-46413374	GATGTAGTCAGAGTGAAATGG <b>CCGGGT</b>
CCR5-2	21	chr3 + 46413579-46413605	GTTGCCCTAAGGATTAATGA <b>ATGAAT</b>
VEGFA_3	21	chr6- 43737522-43737548	GAGAGGGACACACAGATCTAT <b>TGGAA</b>
EMX1-sg1	21	chr2 - 73161167-73161193	GGCCTCCCCAAAGCCTGGCCA <b>GGGAGT</b>
EMX1-sg2	21	chr2 + 73161173-73161199	TGGCCAGGCTTTGGGGAGGCC <b>TGGAGT</b>
EMX1-sg3	20	chr2 + 73160858-73160883	GTGGCTGCTCTGGGGGCCTC <b>CTGAGT</b>
EMX1-sg5	20	chr2- 73161099-73161124	GCAAGCAGCACTCTGCCCTC <b>GTGGGT</b>
EMX1-sg6	20	chr2- 73161167-73161192	GCCTCCCCAAAGCCTGGCCA <b>GGGAGT</b>
EMX1-sg7	20	chr2+ 73161174-73161199	GGCCAGGCTTTGGGGAGGCC <b>TGGAGT</b>

+/- is the genomic orientation of sgRNA. PAM is highlighted in red.

**Table S3. Target sequence in the spacer length and 5' mismatched G experiments**

<b>Site name</b>	<b>Length (bp)</b>	<b>Sequence</b>
VEGFA-15-22	22	TGGGTGAGTGAGTGTGTGCGTG
VEGFA-15-21	21	GGGTGAGTGAGTGTGTGCGTG
VEGFA-15-20	20	GGTGAGTGAGTGTGTGCGTG
VEGFA-15-19	19	GTGAGTGAGTGTGTGCGTG
VEGFA-24-22	22	GGAGAGGGACACACAGATCTAT
VEGFA-24-21	21	GAGAGGGACACACAGATCTAT
VEGFA-24-20	20	AGAGGGACACACAGATCTAT
VEGFA-24-19	19	GAGGGACACACAGATCTAT
VEGFA-25-22	22	GCGTTGGAGCGGGGAGAAGGCC
VEGFA-25-21	21	CGTTGGAGCGGGGAGAAGGCC
VEGFA-25-20	20	GTTGGAGCGGGGAGAAGGCC
VEGFA-25-19	19	TTGGAGCGGGGAGAAGGCC
FANCF_13 (Mismatched G)		(G)GGCAAGGCCCGGCGCACGGTGGCGGGGT
RUNX1_13 (Mismatched G)		(G)GGAAAGAGAGATGTAGGGCTAGAGGGGT
FANCF_10 (Mismatched G)		(G)GGTAGGGCCTTCGCGCACCTCATGGAAT

**Table S4. Primers for targeted deep sequencing.**

Primer name	Sequence	Note
<b>For PCR1</b>		
VEGFA_8.fwd	TACACGACGCTCTCCGATCTTGGGTGAATGGAGCGAGCAG	a
VEGFA_8.rev	TCCTCTCTATGGGCAGTCGGTGATGAGTGACCCCTGGCCTTCTC	a
EMX1_1.fwd	TACACGACGCTCTCCGATCTGGCCTCCTGAGTTTCTCATCT	a
EMX1_1.rev	TCCTCTCTATGGGCAGTCGGTGATGACTCAGGCCCTTCCTCCT	a
EMX1_4.fwd	TACACGACGCTCTCCGATCTAGCCTCAGTCTTCCCATCAG	a
EMX1_4.rev	TCCTCTCTATGGGCAGTCGGTGATTGGAACCACACCTTCACCTG	a
EMX1_6.fwd	TACACGACGCTCTCCGATCTTCGATGTCACCTCCAATGAC	a
EMX1_6.rev	TCCTCTCTATGGGCAGTCGGTGATAGTGGCCAGAGTCCAGCTT	a
EMX1_10.fwd	TACACGACGCTCTCCGATCTAGACACGGAGAGCAGCTG	a
EMX1_10.rev	TCCTCTCTATGGGCAGTCGGTGATCCATTGACAGAGGGACAAGC	a
FANCF_9.fwd	TACACGACGCTCTCCGATCTCAAAGCGCCGATGGATGTG	a
FANCF_9.rev	TCCTCTCTATGGGCAGTCGGTGATGCGGTCTCAAGCACTACCTA	a
FANCF_10.fwd	TACACGACGCTCTCCGATCTATCAGTACGCAGAGAGTCCG	a
FANCF_10.rev	TCCTCTCTATGGGCAGTCGGTGATACGTAGGTAGTCTTGAGACC	a
FANCF_13.fwd	TACACGACGCTCTCCGATCTCAAAGCGCCGATGGATGTG	a
FANCF_13.rev	TCCTCTCTATGGGCAGTCGGTGATGCGGTCTCAAGCACTACCTA	a
FANCF_16.fwd	TACACGACGCTCTCCGATCTATGGATGTGGCGCAGGTAG	a
FANCF_16.rev	TCCTCTCTATGGGCAGTCGGTGATCATGGAATCCCTTCTGCAGC	a
RUNX1_13.fwd	TACACGACGCTCTCCGATCTGAGTCCCAGAGGTATCCAGC	a
RUNX1_13.rev	TCCTCTCTATGGGCAGTCGGTGATTCTCTCTGAAAATGCACCCT	a
RUNX1_14.fwd	TACACGACGCTCTCCGATCTCAAAGTGCATTTCATTACAGG	a
RUNX1_14.rev	TCCTCTCTATGGGCAGTCGGTGATGAGGGTGCATTTTCAGGAGG	a
VEGFA_8.OT1.fwd	TACACGACGCTCTCCGATCTGCTGTGCTATTGAGTGAAAAGT	b
VEGFA_8.OT1.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGCTTGAACACTGAACGT	b
VEGFA_8.OT2.fwd	TACACGACGCTCTCCGATCTGCTCATCTTCAAAGCAGAGG	b
VEGFA_8.OT2.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGATGGGCATTTATTGGAAA	b
VEGFA_8.OT3.fwd	TACACGACGCTCTCCGATCTCAGCGTTTATATGATCTGGAGTAGA	b
VEGFA_8.OT3.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAACCATGGAGGTACAGTAAAACC	b
VEGFA_8.OT4.fwd	TACACGACGCTCTCCGATCTTTTTAAAAAGTTTGTGTACCCTGA	b
VEGFA_8.OT4.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGCACTCACCATGAACAG	b
VEGFA_8.OT5.fwd	TACACGACGCTCTCCGATCTGTGCTTGTGTACCTAAACGTATC	b
VEGFA_8.OT5.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGATCCCCAAAAGTGCCTTCA	b
VEGFA_8.OT6.fwd	TACACGACGCTCTCCGATCTGCCATCCTAGCCATCGTAAA	b
VEGFA_8.OT6.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTGGAGGGAACCTACCGTGA	b
VEGFA_8.OT7.fwd	TACACGACGCTCTCCGATCTCAGAAAAGCTGAGATTTATTATTGAAG	b
VEGFA_8.OT7.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTATAAAGTGGCCGACCTGGA	b
VEGFA_8.OT8.fwd	TACACGACGCTCTCCGATCTGCGTATTACAGGGTGTGCAAT	b
VEGFA_8.OT8.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTGGGAATCTAATGTATGGCA	b
VEGFA_8.OT9.fwd	TACACGACGCTCTCCGATCTCCCGCTCCAACCTCAAATG	b
VEGFA_8.OT9.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGCGGTATGTATGTGTGT	b
EMX1_6.OT1.fwd	TACACGACGCTCTCCGATCTTCTCACACAAAAGCACATGT	b
EMX1_6.OT1.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGCTATACATGCGACTGGT	b
EMX1_6.OT2.fwd	TACACGACGCTCTCCGATCTACAAAAACATAGTGCCTGCTCC	b
EMX1_6.OT2.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGAGCTTCTGTCTTACCCT	b
EMX1_6.OT3.fwd	TACACGACGCTCTCCGATCTCTCCCTCCTTCTTCCACAGG	b
EMX1_6.OT3.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGACAAAACCAACCTTTCCA	b
EMX1_6.OT4.fwd	TACACGACGCTCTCCGATCTCATAGTGCACCTGTCCCTCA	b



EMX1_6.OT4.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCAGACTGAGGTGTTGTTGGC	b
FANCF_13.OT1.fwd	TACACGACGCTCTTCCGATCTGGTCAAAAAGATCTGGGGC	b
FANCF_13.OT1.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCAAGCGCATGTCCACATAAA	b
FANCF_13.OT2.fwd	TACACGACGCTCTTCCGATCTCAAACCTCAAAGGCTGCATCA	b
FANCF_13.OT2.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCATAGAGCCTCTCCTTCCCT	b
FANCF_13.OT3.fwd	TACACGACGCTCTTCCGATCTAACGAGAACCTTCATTTATGCCA	b
FANCF_13.OT3.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGACTAATTGACTACCCACTCACT	b
FANCF_13.OT4.fwd	TACACGACGCTCTTCCGATCTATGTGGGGCAGGTACAGAG	b
FANCF_13.OT4.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGAATTGTGGTGTGTCTGCA	b
FANCF_13.OT5.fwd	TACACGACGCTCTTCCGATCTGAGCAGGATCTTCCAGCACCT	b
FANCF_13.OT5.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAGTACCTCCTGAGCCGC	b
FANCF_13.OT6.fwd	TACACGACGCTCTTCCGATCTCCCGCTCCAGGTTGCGCTGA	b
FANCF_13.OT6.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCGTCGGACCCTCCAAGTG	b
FANCF_13.OT7.fwd	TACACGACGCTCTTCCGATCTACCCTAGTGTGTGACCAC	b
FANCF_13.OT7.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGGTACAGAGTCCAGGCAG	b
FANCF_13.OT8.fwd	TACACGACGCTCTTCCGATCTCGTGGAAAAGTGGCACCC	b
FANCF_13.OT8.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGCCAAACCCAGGAATATTG	b
FANCF_13.OT9.fwd	TACACGACGCTCTTCCGATCTAAGCACAACCAAGGAGAGGG	b
FANCF_13.OT9.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCTTTCAGTCACCTCACCAGT	b
FANCF_13.OT10.fwd	TACACGACGCTCTTCCGATCTTGGGGTTTCATGCTCTCTTCA	b
FANCF_13.OT10.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTCACCCTTTCATCTCTCC	b
RUNX1_13.OT1.fwd	TACACGACGCTCTTCCGATCTACTGGCTTGGATTCTCTTCTCA	b
RUNX1_13.OT1.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCAGGGCGTCAGATTGAAACC	b
VEGFA_15.fwd	TACACGACGCTCTTCCGATCTTGGGTGAATGGAGCAGCAG	b
VEGFA_15.rev	TCCTCTCTATGGGCAGTCGGTGATGAGTGACCCCTGGCCTTCTC	b
VEGFA_24.fwd	TACACGACGCTCTTCCGATCTGAGCCGTTCCCTCTTTGCTA	b
VEGFA_24.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAGAGTGAGGACGTGTGTGT	b
VEGFA_25.fwd	TACACGACGCTCTTCCGATCTGCAGCGTCTTCGAGAGTGAGG	b
VEGFA_25.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGGGGAGAGGGACACACAGAT	b
AAVS1_2.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTGGCTCCATCGTAAGCAAACCTTA	b
AAVS1_2.fwd	TACACGACGCTCTTCCGATCTGGTCTAACCCACCTCTGTGA	b
AAVS1_3.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCACTGTGGGGTGGAGGGGACA	b
AAVS1_3.fwd	TACACGACGCTCTTCCGATCTGGATCCTGTGTCCCCGAGCTG	b
AAVS1_4.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACAGGAGTGGGGGTAGACC	b
AAVS1_4.fwd	TACACGACGCTCTTCCGATCTGCCACTAGGGACAGGATTGGTGACAG	b
AAVS1_5.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCAGAAATGGGGTGTGTCCAC	b
AAVS1_5.fwd	TACACGACGCTCTTCCGATCTAGGCCTCCTCCTCTCTAGTCTC	b
CCR5_1.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCATCTGTGGTGGCAGACGAAACATTT	b
CCR5_1.fwd	TACACGACGCTCTTCCGATCTAGGCAAGACCATCAGATGTTTGGTGA	b
CCR5_2.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCTGTGCTTCAAGTCTTGTCTGCAA	b
CCR5_2.fwd	TACACGACGCTCTTCCGATCTACATGCACTATGAGCAAGCCAGTAAT	b
EMX1_sg1.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGTGGGCCCAAGCTGGACTC	b
EMX1_sg1.fwd	TACACGACGCTCTTCCGATCTATGTCTTGTCCCTCTGTCAATGGC	b
EMX1_sg2.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGTGGGCCCAAGCTGGACTCT	b
EMX1_sg2.fwd	TACACGACGCTCTTCCGATCTGCCTCAGCCAGCCCATTCG	b
EMX1_sg3.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCACTCTCCCATCAGGCTCTCAGCT	b
EMX1_sg3.fwd	TACACGACGCTCTTCCGATCTGGGAGGAGGGGCACAGATGA	b
EMX1_sg5.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGCCAATGGGAGGACATCGATGT	b
EMX1_sg5.fwd	TACACGACGCTCTTCCGATCTTCCAGCTTGGGCCACGCA	b
EMX1_sg6.rev	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCGTGGGCCCAAGCTGGACTC	b

EMX1_sg6.fwd	TACACGACGCTCTCCGATCTATTGCTTGTCCTCTGTCAATGGC	b
EMX1_sg7.rev	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTCGTGGGCCCAAGCTGGACTC	b
EMX1_sg7.fwd	TACACGACGCTCTCCGATCTATTGCTTGTCCTCTGTCAATGGC	b
VEGFA_3.rev	GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTGGAGAAGGCCAGGGGTCAC	b
VEGFA_3.fwd	TACACGACGCTCTCCGATCTGGCAGGGGAAGCCGGAGAG	b
<b>For PCR2</b>		
MI.P501	AATGATACGGCGACCACCGAGATCTACACTAGATCGCANNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P502	AATGATACGGCGACCACCGAGATCTACACTCTCTATNNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P503	AATGATACGGCGACCACCGAGATCTACACTATCTCTNNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P504	AATGATACGGCGACCACCGAGATCTACACAGAGTAGANNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P505	AATGATACGGCGACCACCGAGATCTACACGTAAGGANNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P506	AATGATACGGCGACCACCGAGATCTACACTGCATANNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P507	AATGATACGGCGACCACCGAGATCTACACAAGGAGTANNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
MI.P508	AATGATACGGCGACCACCGAGATCTACACTAAGCCTNNWNNWNNACACTCTTCCCTACACGACGCTCTCCGATC*T	
P7-I-1	CAAGCAGAAGACGGCATAACGAGATTCGCCTTAGTGACTGGAGTTCAGACGTGT	
P7-I-2	CAAGCAGAAGACGGCATAACGAGATCTAGTACGGTGACTGGAGTTCAGACGTGT	
P7-I-3	CAAGCAGAAGACGGCATAACGAGATTTCTGCCTGTGACTGGAGTTCAGACGTGT	
P7-I-4	CAAGCAGAAGACGGCATAACGAGATGCTCAGGAGTGACTGGAGTTCAGACGTGT	
P7-I-5	CAAGCAGAAGACGGCATAACGAGATAGGAGTCCGTGACTGGAGTTCAGACGTGT	
P7-I-6	CAAGCAGAAGACGGCATAACGAGATCATGCCTAGTGACTGGAGTTCAGACGTGT	
P7-I-7	CAAGCAGAAGACGGCATAACGAGATGTAGAGAGTGACTGGAGTTCAGACGTGT	
P7-I-8	CAAGCAGAAGACGGCATAACGAGATCCTCTCTGGTGACTGGAGTTCAGACGTGT	
P7-I-9	CAAGCAGAAGACGGCATAACGAGATAGCGTAGCGTGACTGGAGTTCAGACGTGT	
P7-I-10	CAAGCAGAAGACGGCATAACGAGATCAGCCTCGGTGACTGGAGTTCAGACGTGT	
P7-I-11	CAAGCAGAAGACGGCATAACGAGATTGCCTCTGTGACTGGAGTTCAGACGTGT	
P7-I-12	CAAGCAGAAGACGGCATAACGAGATTCTCTACGTGACTGGAGTTCAGACGTGT	
P7-I-13	CAAGCAGAAGACGGCATAACGAGATAACTTACGTGACTGGAGTTCAGACGTGT	
P7-I-14	CAAGCAGAAGACGGCATAACGAGATTGGAGAGGGTGACTGGAGTTCAGACGTGT	
P7-I-15	CAAGCAGAAGACGGCATAACGAGATACGCATCGGTGACTGGAGTTCAGACGTGT	
P7-I-16	CAAGCAGAAGACGGCATAACGAGATGTACCGTTGTGACTGGAGTTCAGACGTGT	
P7-I-17	CAAGCAGAAGACGGCATAACGAGATTACAGTTAGTGACTGGAGTTCAGACGTGT	
P7-I-18	CAAGCAGAAGACGGCATAACGAGATAATCACTGTGACTGGAGTTCAGACGTGT	
P7-I-19	CAAGCAGAAGACGGCATAACGAGATGTACCTAGTGACTGGAGTTCAGACGTGT	
P7-I-20	CAAGCAGAAGACGGCATAACGAGATCTGGAACAGTGACTGGAGTTCAGACGTGT	
P7-I-21	CAAGCAGAAGACGGCATAACGAGATGGTGACTAGTGACTGGAGTTCAGACGTGT	
P7-I-22	CAAGCAGAAGACGGCATAACGAGATGTCAACCGTGACTGGAGTTCAGACGTGT	
P7-I-23	CAAGCAGAAGACGGCATAACGAGATGCCTGTCTGTGACTGGAGTTCAGACGTGT	
P7-I-24	CAAGCAGAAGACGGCATAACGAGATACTGATGGTGACTGGAGTTCAGACGTGT	
P7-I-25	CAAGCAGAAGACGGCATAACGAGATATGCTAACGTGACTGGAGTTCAGACGTGT	
P7-I-26	CAAGCAGAAGACGGCATAACGAGATCACTGAGTGTGACTGGAGTTCAGACGTGT	
P7-I-27	CAAGCAGAAGACGGCATAACGAGATTAGGCCATGTGACTGGAGTTCAGACGTGT	
P7-I-28	CAAGCAGAAGACGGCATAACGAGATCAGCAGTCGTGACTGGAGTTCAGACGTGT	
P7-I-29	CAAGCAGAAGACGGCATAACGAGATTTCTGAGAGTGACTGGAGTTCAGACGTGT	
P7-I-30	CAAGCAGAAGACGGCATAACGAGATGGACGTTAGTGACTGGAGTTCAGACGTGT	

P7-I-31	CAAGCAGAAGACGGCATAACGAGATGTGTAGGTGTGACTGGAGTTCAGACGTGT	
P7-I-32	CAAGCAGAAGACGGCATAACGAGATCATCTCAGGTGACTGGAGTTCAGACGTGT	
P7-I-33	CAAGCAGAAGACGGCATAACGAGATGCATAGCAGTGTGACTGGAGTTCAGACGTGT	
P7-I-34	CAAGCAGAAGACGGCATAACGAGATCAGTGCACGTGACTGGAGTTCAGACGTGT	
P7-I-35	CAAGCAGAAGACGGCATAACGAGATTTCCGGCATGTGACTGGAGTTCAGACGTGT	
P7-I-36	CAAGCAGAAGACGGCATAACGAGATCAACAGGTGTGACTGGAGTTCAGACGTGT	
P7-I-37	CAAGCAGAAGACGGCATAACGAGATAACACTCGGTGACTGGAGTTCAGACGTGT	
P7-I-38	CAAGCAGAAGACGGCATAACGAGATGTCCTGACGTGACTGGAGTTCAGACGTGT	
P7-I-39	CAAGCAGAAGACGGCATAACGAGATGACGTAGAGTGTGACTGGAGTTCAGACGTGT	
P7-I-40	CAAGCAGAAGACGGCATAACGAGATGATTGGCAGTGTGACTGGAGTTCAGACGTGT	
P7-I-41	CAAGCAGAAGACGGCATAACGAGATGCCACGACGTGACTGGAGTTCAGACGTGT	
P7-I-42	CAAGCAGAAGACGGCATAACGAGATTTGTTACGGTGTGACTGGAGTTCAGACGTGT	
P7-I-43	CAAGCAGAAGACGGCATAACGAGATACGACCTAGTGTGACTGGAGTTCAGACGTGT	
P7-I-44	CAAGCAGAAGACGGCATAACGAGATTGATAATGGTGTGACTGGAGTTCAGACGTGT	
P7-I-45	CAAGCAGAAGACGGCATAACGAGATGGTTCATGTGACTGGAGTTCAGACGTGT	
P7-I-46	CAAGCAGAAGACGGCATAACGAGATCCAGTATCGTGTGACTGGAGTTCAGACGTGT	
P7-I-47	CAAGCAGAAGACGGCATAACGAGATGTCCAGCTGTGACTGGAGTTCAGACGTGT	
P7-I-48	CAAGCAGAAGACGGCATAACGAGATTAACCTTCGTGACTGGAGTTCAGACGTGT	
P7-I-49	CAAGCAGAAGACGGCATAACGAGATATAGGCTGGTGTGACTGGAGTTCAGACGTGT	
P7-I-50	CAAGCAGAAGACGGCATAACGAGATCCACTTGAGTGTGACTGGAGTTCAGACGTGT	
P7-I-51	CAAGCAGAAGACGGCATAACGAGATTGGACCACGTGACTGGAGTTCAGACGTGT	
P7-I-52	CAAGCAGAAGACGGCATAACGAGATTGCGTCAAGTGTGACTGGAGTTCAGACGTGT	
P7-I-53	CAAGCAGAAGACGGCATAACGAGATGTCGTGTAGTGTGACTGGAGTTCAGACGTGT	
P7-I-54	CAAGCAGAAGACGGCATAACGAGATGGAGGCCAGTGTGACTGGAGTTCAGACGTGT	
P7-I-55	CAAGCAGAAGACGGCATAACGAGATCTAGCCTGGTGTGACTGGAGTTCAGACGTGT	
P7-I-56	CAAGCAGAAGACGGCATAACGAGATGCGCGTGTGTGACTGGAGTTCAGACGTGT	
P7-I-57	CAAGCAGAAGACGGCATAACGAGATCATTATGGGTGTGACTGGAGTTCAGACGTGT	
P7-I-58	CAAGCAGAAGACGGCATAACGAGATATTATACGGTGTGACTGGAGTTCAGACGTGT	
P7-I-59	CAAGCAGAAGACGGCATAACGAGATTTAGACTCGTGTGACTGGAGTTCAGACGTGT	
P7-I-60	CAAGCAGAAGACGGCATAACGAGATGTACGCACGTGACTGGAGTTCAGACGTGT	
P7-I-61	CAAGCAGAAGACGGCATAACGAGATGAGCCATCGTGTGACTGGAGTTCAGACGTGT	
P7-I-62	CAAGCAGAAGACGGCATAACGAGATGTGGAGTTCGTGACTGGAGTTCAGACGTGT	
P7-I-63	CAAGCAGAAGACGGCATAACGAGATCAGCTTCGGTGTGACTGGAGTTCAGACGTGT	
P7-I-64	CAAGCAGAAGACGGCATAACGAGATCACAAGTAGTGTGACTGGAGTTCAGACGTGT	
P7-I-65	CAAGCAGAAGACGGCATAACGAGATGATGTGGTGTGACTGGAGTTCAGACGTGT	
P7-I-66	CAAGCAGAAGACGGCATAACGAGATCTTGGAGGGTGTGACTGGAGTTCAGACGTGT	
P7-I-67	CAAGCAGAAGACGGCATAACGAGATCGAACGTCGTGACTGGAGTTCAGACGTGT	
P7-I-68	CAAGCAGAAGACGGCATAACGAGATATTGTCAAGTGTGACTGGAGTTCAGACGTGT	
P7-I-69	CAAGCAGAAGACGGCATAACGAGATGTTCCGGAGTGTGACTGGAGTTCAGACGTGT	
P7-I-70	CAAGCAGAAGACGGCATAACGAGATCCTAACGGGTGTGACTGGAGTTCAGACGTGT	
P7-I-71	CAAGCAGAAGACGGCATAACGAGATATCTGGACGTGACTGGAGTTCAGACGTGT	
P7-I-72	CAAGCAGAAGACGGCATAACGAGATCTATAGACGTGACTGGAGTTCAGACGTGT	
P7-I-73	CAAGCAGAAGACGGCATAACGAGATCTTGGCGGTGTGACTGGAGTTCAGACGTGT	

P7-I-74	CAAGCAGAAGACGGCATAACGAGATAATTAGGCGTGACTGGAGTTCAGACGTGT	
P7-I-75	CAAGCAGAAGACGGCATAACGAGATCGTGTAGTGTGACTGGAGTTCAGACGTGT	
P7-I-76	CAAGCAGAAGACGGCATAACGAGATTGCCAACAGTGACTGGAGTTCAGACGTGT	
P7-I-77	CAAGCAGAAGACGGCATAACGAGATTACACAAGGTGACTGGAGTTCAGACGTGT	
P7-I-78	CAAGCAGAAGACGGCATAACGAGATTAAGTAGGGTGACTGGAGTTCAGACGTGT	
P7-I-79	CAAGCAGAAGACGGCATAACGAGATATAGTGTGTGACTGGAGTTCAGACGTGT	
P7-I-80	CAAGCAGAAGACGGCATAACGAGATATGTAATAGTGACTGGAGTTCAGACGTGT	
P7-I-81	CAAGCAGAAGACGGCATAACGAGATACTTGGTGGTGACTGGAGTTCAGACGTGT	
P7-I-82	CAAGCAGAAGACGGCATAACGAGATCAGTCTAGGTGACTGGAGTTCAGACGTGT	
P7-I-83	CAAGCAGAAGACGGCATAACGAGATTGACGCCCTGTGACTGGAGTTCAGACGTGT	
P7-I-84	CAAGCAGAAGACGGCATAACGAGATACCATGTAGTGACTGGAGTTCAGACGTGT	
P7-I-85	CAAGCAGAAGACGGCATAACGAGATTTACCGACGTGACTGGAGTTCAGACGTGT	
P7-I-86	CAAGCAGAAGACGGCATAACGAGATCCAGAAGTGACTGGAGTTCAGACGTGT	
P7-I-87	CAAGCAGAAGACGGCATAACGAGATAGGTTGCTGTGACTGGAGTTCAGACGTGT	
P7-I-88	CAAGCAGAAGACGGCATAACGAGATCTGAGTGAGTGACTGGAGTTCAGACGTGT	
P7-I-89	CAAGCAGAAGACGGCATAACGAGATGGTACTGTGTGACTGGAGTTCAGACGTGT	
P7-I-90	CAAGCAGAAGACGGCATAACGAGATTTGGTGCCGTGACTGGAGTTCAGACGTGT	
P7-I-91	CAAGCAGAAGACGGCATAACGAGATTTCCGATGGTGACTGGAGTTCAGACGTGT	
P7-I-92	CAAGCAGAAGACGGCATAACGAGATCCGTATATGTGACTGGAGTTCAGACGTGT	
P7-I-93	CAAGCAGAAGACGGCATAACGAGATTATCGACAGTGACTGGAGTTCAGACGTGT	
P7-I-94	CAAGCAGAAGACGGCATAACGAGATATAGCCGAGTGACTGGAGTTCAGACGTGT	
P7-I-95	CAAGCAGAAGACGGCATAACGAGATGATCGGTTGTGACTGGAGTTCAGACGTGT	
P7-I-96	CAAGCAGAAGACGGCATAACGAGATAATGGTTCGTGACTGGAGTTCAGACGTGT	

a. PCR2: use one of the MIP.5##s and one of the P7##s (list in Table S5). Requires custom sequencing primers Index 1 and Read2 (list in Table S5).

b. PCR2: use one of the MIP.5##s and one of the P7-I-##s in PCR2. Compatible with standard Illumina sequencing primers.

\* Indicates a phosphorothioate bond modification.

**Table S5. Adaptor and primer sequences for GUIDE-seq.**

Note: Each adaptor is formed by using one TOP and one corresponding BOT oligos, with the following annealing program: 95°C for 1 min; slow ramping down at -0.2°C/sec to 4°C.

TOP.ID	TOP.oligo.seq	BOT.ID	BOT.oligo.seq
TOP001	TACACGACGCTCTCCGATCTNNWNNWNATGCCANTGCCGTT	BOT001	/5Phos/ACGGCANTGGCAT/3Phos/
TOP002	TACACGACGCTCTCCGATCTNNWNNWNACCATCNCAACGAT	BOT002	/5Phos/TCGTTGNATGGT/3Phos/
TOP003	TACACGACGCTCTCCGATCTNNWNNWNGTGGCCNACTACT	BOT003	/5Phos/GTAGTANGGCCAC/3Phos/
TOP004	TACACGACGCTCTCCGATCTNNWNNWNGGAGTTNGAGGTGT	BOT004	/5Phos/CACCTCNACTCC/3Phos/
TOP005	TACACGACGCTCTCCGATCTNNWNNWNATTGCANAGCAACT	BOT005	/5Phos/GTTGCTNTGCAAT/3Phos/
TOP006	TACACGACGCTCTCCGATCTNNWNNWNATAACNCGAGTAT	BOT006	/5Phos/TACTCGNNTGTA/3Phos/
TOP007	TACACGACGCTCTCCGATCTNNWNNWNTGCGTTNCTAGCGT	BOT007	/5Phos/CGCTAGNAACGCA/3Phos/
TOP008	TACACGACGCTCTCCGATCTNNWNNWNTGTCNCNTCTCACT	BOT008	/5Phos/GTGAGANGGAACA/3Phos/
TOP009	TACACGACGCTCTCCGATCTNNWNNWNTGACATNCCTCGAT	BOT009	/5Phos/GGCAGTNGTATCG/3Phos/
TOP010	TACACGACGCTCTCCGATCTNNWNNWNGATACNACTGCCT	BOT010	/5Phos/GGAGTNGTATCG/3Phos/
TOP011	TACACGACGCTCTCCGATCTNNWNNWNTCTGCGNAGTCTGT	BOT011	/5Phos/CAGACTNCGAGA/3Phos/
TOP012	TACACGACGCTCTCCGATCTNNWNNWNTCTGCGNAGTCTGT	BOT012	/5Phos/GACTCCNGAAGA/3Phos/
TOP013	TACACGACGCTCTCCGATCTNNWNNWAGGCTTACGTGTT	BOT013	/5Phos/ACACGTNAAGCT/3Phos/
TOP014	TACACGACGCTCTCCGATCTNNWNNWNTCAGANGTCACAT	BOT014	/5Phos/TGTGACNCTGTA/3Phos/
TOP015	TACACGACGCTCTCCGATCTNNWNNWAGCCGNGAGATAT	BOT015	/5Phos/TACTCTNCCGGT/3Phos/
TOP016	TACACGACGCTCTCCGATCTNNWNNWNATGGAANGTGGCT	BOT016	/5Phos/GCCACNTTCCAT/3Phos/
TOP017	TACACGACGCTCTCCGATCTNNWNNWAGACACNAATGTT	BOT017	/5Phos/ACATTGNGTGTCT/3Phos/
TOP018	TACACGACGCTCTCCGATCTNNWNNWNGGATGNTCATAGT	BOT018	/5Phos/CTATGANACTACC/3Phos/
TOP019	TACACGACGCTCTCCGATCTNNWNNWNATCGAGNGATCTAT	BOT019	/5Phos/TAGATCNCTCGAT/3Phos/
TOP020	TACACGACGCTCTCCGATCTNNWNNWNCAACAANTGCCAAT	BOT020	/5Phos/TTGGCANTTGTG/3Phos/
TOP021	TACACGACGCTCTCCGATCTNNWNNWNGTGAANCCAATCT	BOT021	/5Phos/GATTGGNTGCAC/3Phos/
TOP022	TACACGACGCTCTCCGATCTNNWNNWNACAATGNTCACAGT	BOT022	/5Phos/CTGTGANCATTGT/3Phos/
TOP023	TACACGACGCTCTCCGATCTNNWNNWNGGCTCTNAACGTAT	BOT023	/5Phos/TACGTTNAGAGCC/3Phos/
TOP024	TACACGACGCTCTCCGATCTNNWNNWNTCCACNATCCTT	BOT024	/5Phos/AGGAATNGTGGC/3Phos/
TOP025	TACACGACGCTCTCCGATCTNNWNNWNAAGCGNCTCCTT	BOT025	/5Phos/AAGGAGNCGCCTT/3Phos/
TOP026	TACACGACGCTCTCCGATCTNNWNNWNGAGACANGTGGAAT	BOT026	/5Phos/TTCCACNTGTCT/3Phos/
TOP027	TACACGACGCTCTCCGATCTNNWNNWNATGCGTNAATGCAT	BOT027	/5Phos/TGCATTNACGCAT/3Phos/
TOP028	TACACGACGCTCTCCGATCTNNWNNWNATAAGNTGGTCCT	BOT028	/5Phos/GGACCANCTTGA/3Phos/
TOP029	TACACGACGCTCTCCGATCTNNWNNWNACTCTNTGTGTTT	BOT029	/5Phos/AACACANAGGAGT/3Phos/
TOP030	TACACGACGCTCTCCGATCTNNWNNWNGGAGCNCCTGTCT	BOT030	/5Phos/GACAAGNGCTCCA/3Phos/
TOP031	TACACGACGCTCTCCGATCTNNWNNWNCAACTGNTCAGACT	BOT031	/5Phos/GTCTGANCAGTTG/3Phos/
TOP032	TACACGACGCTCTCCGATCTNNWNNWNTCAGATNACCAGCT	BOT032	/5Phos/GCTGGTNATCTGA/3Phos/
TOP033	TACACGACGCTCTCCGATCTNNWNNWNTGGCCGNTACTGT	BOT033	/5Phos/CAGTAANCGGCCA/3Phos/
TOP034	TACACGACGCTCTCCGATCTNNWNNWNGGCTCTNAATCACT	BOT034	/5Phos/GTGATTNAGCACC/3Phos/
TOP035	TACACGACGCTCTCCGATCTNNWNNWNCATACGNATACAGT	BOT035	/5Phos/CTGTATNCGTATG/3Phos/
TOP036	TACACGACGCTCTCCGATCTNNWNNWNTGAATANCTGGCT	BOT036	/5Phos/GCCAGGNTATCA/3Phos/
TOP037	TACACGACGCTCTCCGATCTNNWNNWNGTGGTCNATCGTAT	BOT037	/5Phos/TACGATNGACCAC/3Phos/
TOP038	TACACGACGCTCTCCGATCTNNWNNWNGAACCTNATGACAT	BOT038	/5Phos/TGTCATNAGGTTT/3Phos/
TOP039	TACACGACGCTCTCCGATCTNNWNNWNACGANCTATAGT	BOT039	/5Phos/CTATAGNTCGTGT/3Phos/
TOP040	TACACGACGCTCTCCGATCTNNWNNWNATGTCNGAGACTT	BOT040	/5Phos/AGTCTCNGCATAT/3Phos/
TOP041	TACACGACGCTCTCCGATCTNNWNNWNCCTTANGTGTGT	BOT041	/5Phos/CAGCACNTAAGCG/3Phos/
TOP042	TACACGACGCTCTCCGATCTNNWNNWNACTACTNAGGATT	BOT042	/5Phos/ATCCTCAGTAGT/3Phos/
TOP043	TACACGACGCTCTCCGATCTNNWNNWNGCTCCGNACCATAT	BOT043	/5Phos/TATGGTNCGGAGC/3Phos/
TOP044	TACACGACGCTCTCCGATCTNNWNNWNTTCCGCNATAGTGT	BOT044	/5Phos/CACTATNGCCGAA/3Phos/
TOP045	TACACGACGCTCTCCGATCTNNWNNWNTTAGAGNCCATGCT	BOT045	/5Phos/GCATGGNCTTAA/3Phos/
TOP046	TACACGACGCTCTCCGATCTNNWNNWAGGTGANGTCTAT	BOT046	/5Phos/TAGAANTCACCT/3Phos/
TOP047	TACACGACGCTCTCCGATCTNNWNNWNAACATTNGCAGGTT	BOT047	/5Phos/ACCTGCNAATGTT/3Phos/
TOP048	TACACGACGCTCTCCGATCTNNWNNWNGTGGCNATGGAAT	BOT048	/5Phos/TTCCATNGCCACC/3Phos/

**Primers used in enrichment PCR1 and PCR2**

Primer	sequence	Note
--------	----------	------

OFF_GSP1_-	GGATCTCGACGCTCTCCCTGTTTAAATTGAGTTGTCATATGTTAATAAC	for PCR1
OFF_GSP1_+	GGATCTCGACGCTCTCCCTATACCGTTATTAACATATGACA	for PCR1
OFF_GSP2_-	CCTCTCTATGGGCAGTCGGTGATACATATGACAACTCAATTAAAC	for PCR2
OFF_GSP2_+	CCTCTCTATGGGCAGTCGGTGATTTGAGTTGTCATATGTTAATAACGGTA	for PCR2
P558	AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT	for PCR2
P701	CAAGCAGAAGACGGCATAACGAGATTTCGCTTAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	for PCR2
P702	CAAGCAGAAGACGGCATAACGAGATCTAGTACGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P703	CAAGCAGAAGACGGCATAACGAGATTTCTGCCTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P704	CAAGCAGAAGACGGCATAACGAGATGCTCAGGAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P705	CAAGCAGAAGACGGCATAACGAGATAGGAGTCCGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P706	CAAGCAGAAGACGGCATAACGAGATCAGCCTAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P707	CAAGCAGAAGACGGCATAACGAGATGTAGAGAGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P708	CAAGCAGAAGACGGCATAACGAGATCCTCTCTGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P709	CAAGCAGAAGACGGCATAACGAGATAGCGTAGCGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P710	CAAGCAGAAGACGGCATAACGAGATCAGCCTCGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P711	CAAGCAGAAGACGGCATAACGAGATTGCCCTTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P712	CAAGCAGAAGACGGCATAACGAGATTCCTCTACGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P713	CAAGCAGAAGACGGCATAACGAGATAACTTCACGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P714	CAAGCAGAAGACGGCATAACGAGATTGGAGAGGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P715	CAAGCAGAAGACGGCATAACGAGATACGCATCGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P716	CAAGCAGAAGACGGCATAACGAGATGTACCGTTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P717	CAAGCAGAAGACGGCATAACGAGATTACAGTTAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P718	CAAGCAGAAGACGGCATAACGAGATAATCAACTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P719	CAAGCAGAAGACGGCATAACGAGATGTACCTAGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P720	CAAGCAGAAGACGGCATAACGAGATCTGGAACAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P721	CAAGCAGAAGACGGCATAACGAGATGGTGACTAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P722	CAAGCAGAAGACGGCATAACGAGATGTGCAACCGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P723	CAAGCAGAAGACGGCATAACGAGATGCCTGTCTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P724	CAAGCAGAAGACGGCATAACGAGATACTGATGGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P725	CAAGCAGAAGACGGCATAACGAGATATGCTAACGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P726	CAAGCAGAAGACGGCATAACGAGATCACTGAGTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P727	CAAGCAGAAGACGGCATAACGAGATTAGGCCATGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P728	CAAGCAGAAGACGGCATAACGAGATCAGCAGTCGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P729	CAAGCAGAAGACGGCATAACGAGATTTCTGAGAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P730	CAAGCAGAAGACGGCATAACGAGATGGACGTTAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P731	CAAGCAGAAGACGGCATAACGAGATGTGTAGGTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P732	CAAGCAGAAGACGGCATAACGAGATCATCTCAGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P733	CAAGCAGAAGACGGCATAACGAGATGCATAGCAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P734	CAAGCAGAAGACGGCATAACGAGATCAGTGCACGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P735	CAAGCAGAAGACGGCATAACGAGATTTCCGCATGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P736	CAAGCAGAAGACGGCATAACGAGATCAACAGGTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P737	CAAGCAGAAGACGGCATAACGAGATAACACTCGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P738	CAAGCAGAAGACGGCATAACGAGATGCTCCTGACGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P739	CAAGCAGAAGACGGCATAACGAGATGACGTAGAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P740	CAAGCAGAAGACGGCATAACGAGATGATTGGCAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P741	CAAGCAGAAGACGGCATAACGAGATGCCACGACGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P742	CAAGCAGAAGACGGCATAACGAGATTTGTTACGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P743	CAAGCAGAAGACGGCATAACGAGATACGACCTAGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P744	CAAGCAGAAGACGGCATAACGAGATTTGATAATGGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P745	CAAGCAGAAGACGGCATAACGAGATGGTTCATGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P746	CAAGCAGAAGACGGCATAACGAGATCCAGTATCGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P747	CAAGCAGAAGACGGCATAACGAGATGTCCAGTGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
P748	CAAGCAGAAGACGGCATAACGAGATTAACCTTCGTGACTGGAGTCTCTCTATGGGCAGTCGGTGA	
Index1	ATCACCGACTGCCCATAGAGAGGACTCCAGTAC (Custom sequencing primer Index1)	
Read2	GTGACTGGAGTCTCTCTATGGGCAGTCGGTGAT (Custom sequencing primer Read2)	

## Reference

1. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* **26**, 589–95 (2010).
2. Tsai, S. Q. *et al.* GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat. Biotechnol.* **33**, 187–198 (2015).
3. Zheng, Z. *et al.* Anchored multiplex PCR for targeted next-generation sequencing. *Nat. Med.* **20**, 1479–1484 (2014).
4. Bushnell, B. BBDMap (version 37.75) [Software]. Available at <https://sourceforge.net/projects/bbmap/> (2015).
5. Tsai, S. Q., Topkar, V. V., Joung, J. K. & Aryee, M. J. Open-source guideseq software for analysis of GUIDE-seq data. *Nat. Biotechnol.* (2016). doi:10.1038/nbt.3534
6. Minoche, A. E., Dohm, J. C. & Himmelbauer, H. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and Genome Analyzer systems. *Genome Biol.* **12**, R112 (2011).
7. Team, R. C. R: A Language and Environment for Statistical Computing. *Vienna, Austria* (2018).
8. Wickham, H. & Francois, R. Dplyr:Dplyr: a Grammar of Data Manipulation. *Cran* (2014).
9. Wickham, H. & Henry, L. tidyr: Easily Tidy Data with ‘spread()’ and ‘gather()’ Functions. *R Packag. version 0.8.0.* <https://CRAN.R-project.org/package=tidyr> (2018).
10. Valero-Mora, P. M. ggplot2: Elegant Graphics for Data Analysis . *J. Stat. Softw.* (2015). doi:10.18637/jss.v035.b01
11. Chen, H. & Boutros, P. C. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. *BMC Bioinformatics* **12**, 35 (2011).